Author Archives: admin


Horizon Research Fellow job with UNIVERSITY OF LEEDS | 203439 – Times Higher Education (THE)

Would you like to be involved in cutting edge research to develop novel solutions for smart resorbable bone implants for controllable and fast bone restoration, and to testa new generation acellular scaffold with bone-like architecture? Are you interested in acquiring and/or developing your skills to develop new tissue engineering solutions for in vitro reprogramming of adult stem cells for embedding into the smart implant?

Applications are invited for a Postdoctoral Fellow position working with Prof Peter Giannoudis and Dr Elena Jones on the Horizion 2020project SBR Smart Resorbable Bone and a small industry funded project Greenbone. Based on the St. James Campus, you will co-ordinate projects related to several SBR Work Packages (WPs).

More specifically you will be working on the WPs 6 with the aims to:

You will also be responsible for delivering Greenbone project to assess the biological support that GreenBone scaffold can provide for MSCs and endothelial cells.

Reporting to Dr Jones, your work will be carried out in collaboration with consortium members based in Patras, Greece and Munich, Germany.

Capitalising on the infrastructure and samples collected through the Leeds Institute of Rheumatic and Musculoskeletal medicine based across St Jamess University Hospital and LGI, you will generate primary MSC cells to be used by other consortium partners. You will develop and validate assays to assess the behaviour of MSCs on electrospun biocompatible scaffolds, as well as optimise the MSCs uptake of several bioactive DDRs. In collaboration with partners in Greece and Germany, you will also develop and validate assays for the assessment of MSC functionality on bioactive implants. In Greenbone project, you will be testing the attachment and growth of human bone marrow cells onGreenBone scaffold, as well as the endothelial cell-MSC interactions on the scaffold surface.

The post holder will also liaise with the research group, specifically dedicated to this project, and based in the School of Chemical and Process Engineering, as required.

To explore the post further or for any enquiries you may have, please contact:

Dr Elena Jones, Associate Professor (Non-Clinical)

Tel: +44 (0)113 2065647; email:e.jones@leeds.ac.uk

OR

Professor Peter Giannoudis, Professor of Orthopaedic Surgery

Tel + 44 (0) 113 0113-20-67068; email:P.Giannoudis@leeds.ac.uk.

Further Information

The University of Leeds is committed to providing equal opportunities for all and offers a range offamily friendly policies. The University is a charter member of Athena SWAN and holds the Bronzeaward. The School of Medicine holds theGoldaward. We are committed to being an inclusive medical school that values all staff, and we are happy to consider job share applications and requests for flexible working arrangements from our employees.

Location:Leeds - St James University HospitalFaculty/Service:Faculty of Medicine & HealthSchool/Institute:Leeds Institute of Rheumatic & Musculoskeletal Medicine (LIRMM)Section:Section of Experimental RheumatologyCategory:ResearchGrade:Grade 7Salary:33,797 to 40,322 p.a.Working Time:100% FTEPost Type:Full TimeContractType:Fixed Term (Available immediately on a fixed term basis for 27 months or until 31 December 2023 (wichever is sooner))ClosingDate:Tuesday 21 April 2020Reference:MHLRM1130Downloads:CandidateBrief

See more here:
Horizon Research Fellow job with UNIVERSITY OF LEEDS | 203439 - Times Higher Education (THE)

Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical…

SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) -- Predictive Biology, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (Predictive or The Company), announced that on April 9th it submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for the immediate use of mesenchymal stem cells (MSCs) derived from umbilical cord tissue for the treatment of Acute Respiratory Distress Syndrome (ARDS), secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19).

The pandemic caused by COVID-19 has shown to develop into severe ARDS in 30% of hospitalized patients with a 22%-62% mortality rate (Murthy et al., 2020) for those requiring hospitalization in an intensive care unit. Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.

Coronavirus can be deadly, in large part because the virus can cause cytokine storms in which the patients own immune system triggers a runaway response causing more damage to the patient, than to the virus it's trying to eliminate, said John Sorrentino, Chairman of Predictive Technology Group. Respiratory distress kills hundreds of thousands of people each year worldwide. There is clinical data from early clinical trials that seem to indicate that the avoidance of the cytokine storm utilizing MSCs may be a critical component for the treatment of COVID-19 infected patients.

A recent review article published in Pain Physician, concluded that, The limited but emerging evidence regarding UC MSC [umbilical cord mesenchymal stem cells] in managing COVID-19 suggests that it might be considered for compassionate use in critically ill patients to reduce morbidity and mortality in the United States.

The proposed IND clinical trial will utilize Predictives proprietary core technology of naturally occurring MSCs derived from umbilical cord tissue (UC-MSCs) to assess the efficacy as an add-on therapy to standard treatment of patients with severe Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19.

Predictives UC MSC product, CoreCyte, [currently regulated by the FDA as a tissue-based product under 21 CFR 1271.3(d)(1) and Section 361 of the Public Health Service Act] has already beenused as an allograft in over50,000 patients. Physicians have reported to Predictive that over 1,100 patients have been treated with CoreCyte via intravenous administration. No serious adverse events have been reported with CoreCyte regardless of the route of administration. If Predictives EUA request is approved, CoreCyte would be available immediately to critically ill patients with ARDS due to COVID-19 infections.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care. The Companys entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.

Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictives tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit http://www.predtechgroup.com

About Predictive Biotech, Inc.

Predictive Biotech is a leader in regenerative medicine, its products are derived from tissue sources rich in properties that support the bodys natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Predictives signature products are uniquely born from the Whartons jelly layer of the umbilical cord and amniotic fluid and tissue.

With over 100,000 units delivered, product safety and consistency has been realized by thousands of practices throughout the United States. A national network of clinics, health systems, researchers and physicians leverage Predictives four proprietary products: AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte.

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks The Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect The Company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect The Company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by The Company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Predictive BiotechInfo@predictivebiotech.com888-407-9761

Investor ContactJeremy FefferLifeSci Advisorsjeremy@lifesciadvisors.com212-915-2568

The rest is here:
Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical...

Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3…

More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patients

Phase 2 trial - As of last week, 12 patients enrolled from 2 sites; 3 more sites to initiate enrollment this week, for a total of 5 sites

Phase 2b/3 trial - First hospital cleared to enroll patients beginning today

VANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today a comprehensive update and overview of the therapeutic indications from over 30 COVID-19 patients recently treated with leronlimab in over 4 hospitals and clinics throughout the country. More than 25 hospitals, to date, have requested participation in the Companys trials.

Patient enrollment in the Companys two clinical trials and Emergency Investigational New Drug (EIND) is as follows:

-- More than 25 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA). -- Rate of response in mild-to-moderate patients under EIND has been very promising with the first five patients treated being removed from oxygen. -- As of last week, 12 patients have been treated in the Phase 2 trial for mild-to-moderate COVID-19 indications and, because it is a double-blinded, placebo-controlled trial, results are not yet available. -- First site cleared to enroll patients in Phase 2b/3 beginning today.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We continue to coordinate around the clock with healthcare professionals across the country to deliver leronlimab to patients and we are in regular contact with the FDA to ensure they receive current patient data. We are planning to rapidly enroll 75 patients and report the results to the FDA as quickly as possible.

About Coronavirus Disease 2019SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEO RedChip Companies Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com

Read more from the original source:
Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3...

CDC removes chloroquine from guidance on COVID-19 therapy – Tampa Bay Times

Earlier this week, the U.S. Centers for Disease Control and Prevention removed from its website guidance telling doctors how to prescribe and treat COVID-19 patients with hydroxychloroquine and chloroquine, anti-malarial drugs recommended by President Donald Trump and later, Gov. Ron DeSantis, to treat COVID-19. the disease caused by the novel coronavirus.

The guidance originally said: Although optimal dosing and duration of hydroxychloroquine for treatment of COVID-19 are unknown, some U.S. clinicians have reported anecdotally on several ways to prescribe the medication of COVID-19, and listed suggested dosages.

As of Tuesday, the website no longer includes dosing information and instead says: There are no drugs or other therapeutics approved by the U.S. Food and Drug Administration to prevent or treat COVID-19.

Meanwhile in Florida the demand for the drug from the governors office continues to ramp up, while medical professionals are practicing more caution given the scant evidence of the drugs effectiveness.

At a briefing Tuesday, the same day the CDC walked back guidance on the drug, DeSantis gave it a shout-out. He said he loosened shipments from India to free up supplies in the state, and played testimonials on the drug from Florida doctors and a patient via livestream.

A few weeks prior, Trump praised the pairing of hydroxychloroquine and azithromycin, an antibiotic, saying they have a real chance to be one of the biggest game changers in the history of medicine.

He has touted it at several coronavirus task force briefings since, despite hesitation from NIAID Director Anthony Fauci, who warned that making claims is premature without a clinical trial and a randomized study.

Soon after Trumps initial announcement, the Food and Drug Administration authorized emergency use of the drug for COVID-19 patients who are severely ill and hospitalized. The order also lifted restrictions on the drugs manufacturer to get more of the medication. The drug is often prescribed for patients with lupus.

As this thing was first discussed in Washington and the FDA made their decision on it ... I reached out to physicians and just, you know, asked them, Hey, whats the deal with this? DeSantis said Tuesday. We want to obviously give patients all the opportunities toward recovering.

Israeli-based Teva Pharmaceuticals provided Florida with a shipment of hydroxychloroquine this week, following a shipment sent last month, Politico Florida reported.

Doctors and scientists have expressed some skepticism over use of the drug, especially given the lack of research and testing from the global medical community.

I usually dont take medical advice from governors, said Dr. Dushyantha Jayaweera, a physician and researcher at the University of Miami Health System and the Miller School of Medicine. We are not under pressure from anybody.

Jayaweera, who is beginning his own randomized trial of 15,000 Florida health care workers and first responders in the coming weeks, said while University of Miami physicians are using hydroxychloroquine for what is called off-label use in COVID-19 patients, everything is very fluid when it comes to how patients respond.

While early studies have shown that the drug does work to reduce viral load in sick patients, the studies arent perfect. Patients may be receiving other types of drugs or stem cell treatments that could impact their results.

There are also risks. The potential side effects of hydroxychloroquine were highlighted by the Mayo Clinic last month, and came to light recently after a hospital in France stopped using the drug on at least one coronavirus patient after it became a major risk to their cardiac health.

These are quick and dirty studies ... the general consensus is that we want to have a clinical trial, Jayaweera said. In the scientific community, we have to answer the basic questions.

Meanwhile, doctors are doing what they can to make sure as many patients as possible survive. Jayaweera said he and others use hydroxychloroquine because theres no other option but that he doesnt recommend it as a policy.

When patients are sick you are very nervous to do a randomized control trial [of a drug], he said. You give the best thing you can think of for the patient because its an emergency.

On Thursday, the Wall Street Journal reported that Chinese doctors who have been treating coronavirus patients with chloroquine for months say there is no clear evidence the drug is effective against COVID-19.

On a conference call hosted by the Miami Chamber of Commerce Thursday, Department of Emergency Management Director Jared Moskowitz clarified that the state is not making any recommendations when it comes to treating COVID-19 patients.

We are leaving it up to hospitals and doctors and medical practitioners at the local level to make those decisions, he said.

Dr. Eneida Roldan, a physician and CEO of the FIU Health Care Network who was also on the call, warned of instances where people have treated themselves with the drug, like an Arizona man who died after officials said they treated themselves with a popular fish tank additive that has the same active ingredient as the anti-malaria drug.

You need to follow your doctors orders, not just going on a website and buying hydroxychloroquine, she said.

However, she noted the drugs could help patients under the proper care of a doctor.

Theres still a lot of unknowns, but we know for a fact that patients have done very well under the observation of a doctor, she said.

The back-and-forth comes as a clinical trial by the National Institutes of Health began Thursday to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with COVID-19 with the first participants now enrolled in Tennessee.

James Kiley, director of the Division of Lung Diseases under the National Institutes of Health, said in a statement that while hydroxychloroquine has showed promise in a lab setting, its hard to know its potential efficacy in studies with patients.

We really need clinical trial data to determine whether hydroxychloroquine is effective and safe in treating COVID-19, he said.

GET THE DAYSTARTER MORNING UPDATE: Sign up to receive the most up-to-date information on COVID-19 and Tampa Bay, six days a week

UNEMPLOYMENT Q&A: We answer your questions about Florida unemployment benefits

CONTRIBUTE TO THE SCRAPBOOK: Help us tell the story of life under coronavirus

MEET THE HELPERS: Highlighting Tampa Bays everyday heroes in this crisis

FOLLOW OUR COVERAGE ON SOCIAL MEDIA: Facebook. Instagram. Twitter. Reddit.

LISTEN TO THE CORONAVIRUS PODCAST: New episodes every week, including interviews with experts and reporters

HAVE A TIP?: Send us confidential news tips

Were working hard to bring you the latest news on the coronavirus in Florida. This effort takes a lot of resources to gather and update. If you havent already subscribed, please consider buying a print or digital subscription.

Continue reading here:
CDC removes chloroquine from guidance on COVID-19 therapy - Tampa Bay Times

Stem Cell Therapy Market Set to Witness an Uptick during 2017 to 2025 – Science In Me

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

See original here:
Stem Cell Therapy Market Set to Witness an Uptick during 2017 to 2025 - Science In Me

A Quarantine Trendsetter – Long Island Weekly News

Coronavirus (Image source: U.S. Department of State)

In my February column, I wrote about the fact that I had a stem cell transplant in early December 2019, about a month before I heard for the first time about the coronavirus.

The transplant entailed getting an unrelated donors stem cells to replace mine; then, if all went according to plan, these cells would grow into a new immune system to seek and destroy my cancer cells.

As a result of the transplant, all of my childhood vaccinations became ineffective. I was instructed to stay in isolation for at least four months in order to avoid infectious and possibly deadly diseases like influenza. Consequently, I have been quarantined since December.

Just a day before writing this, a friend told me that Im a trendsetter.

I knew very little about viruses before the coronavirus came alongonly that they were microscopic infectious organisms that invade living cells and then reproduce. In an effort to review what I had been (mostly unconsciously) protected from before transplant, I Googled the Centers for Disease Control and Prevention (CDC) and found a piece entitled, Vaccines for children: Diseases you almost forgot about.

I was reminded that most of us had vaccines as children for some of the nastiest viruses, including polio, which invades the brain and spinal cord and leads to paralysis; tetanus, a potentially fatal disease that causes lockjaw; whooping cough, which can lead to violent coughing that makes it difficult to breathe; and many more.

Most older adults are familiar with chicken pox, mumps and measles. I had two of them as a young teenager. One that I forgot about is diphtheria, which affects breathing or swallowing and can lead to heart failure, paralysis and death. There are several more.

I imagined the panic that parents must have felt and the pain that young children must have experienced before vaccines were discovered to prevent these horrible infectious diseases.

For the time being, I cannot replace my old vaccines. I must wait for at least one year while my new immune system gets stronger.

The idea of being in isolation and maintaining a safe social distance for a few months post-transplant made sense to me. I was well prepared by doctors and nurses and I knew my wife would be a great caregiver, so I thought I could do the time.

And then, the coronavirus came along.

For me, being quarantined was an old hat by the time a national emergency was declared and everything started to shut down. I learned that this new virus main target was the lungs and people older than 60 years with underlying health conditions were its primary targets.

I fit the bill and knew that Id have to do more time: at least another three months, my transplant doctor told me. The only difference is that this time, hundreds of millions of people would be joining me.

I was well-prepared before and after my transplant. I knew why I had to self-isolate and for how long. No one, including me, was prepared for COVID-19 and the mass quarantine that it now requiresnot only to protect oneself and ones family, but also to protect strangers. Mostly older strangers like me.

Scientists and other health professionals were the heroes of viral epidemics gone by. I do believe we will get through this, with people like immunologist Dr. Anthony Fauci leading the way.

Still, the unknown is what is most frightening. We all want answers, yet some remain illusive at the moment. This is an opportunity for all of us to strengthen our tolerance for ambiguity.

When will this end? No clue. Will it come back? No idea.

Although my new immune system needs more time to protect me, I just found out after a PET scan that Im in complete remission from my cancer.

Will it come back? No idea.

We are all in the same boat, living in uncertainty, whether young or old, healthy or unwell. As Plato said, Be kind, for everyone you meet is fighting a harder battle.

Andrew Malekoff is the executive director of North Shore Child and Family Guidance Center. To find out more, call 516-626-1971 or visit http://www.northshorechildguidance.org.

Go here to see the original:
A Quarantine Trendsetter - Long Island Weekly News

What We Know About Masks and the New Coronavirus – The New Yorker

So, going back to your question about the argument against the public wearing masks, I think that there was a mixture of concern that the public would hoard and that it would create alarm. But, to this point, we are in alarming circumstances, and the risk is non-zero. Lets say in the worst-case scenario that masks only offer fifty-per-cent protection. Well, fifty per cent is better than zero. And it seems to me, more and more, that the C.D.C. and the White House have come around to the idea that people should be wearing masks.

The other arguments I have read against them were about people scratching and touching their faces more, or about the difficulty of cleaning them, which introduces another risk.

If we ask the public to wear masks, whatever masks they are, we need a simple decontamination protocol. Because what we dont want is people to wear masks, and feel safe, whereas, in fact, they are collecting respiratory droplets. So we need a simple decontamination protocol.

What about cleaning masks? The C.D.C. says that they should be routinely washed, and that a washing machine should suffice.

You should follow the C.D.C. recommendations, but Im not aware of a lot of empirical data about whether washing degrades the fibres, and it would be very helpful if someone produced that data. I am agnostic, to be honest. If washing works, it works. I am totally fine with washing. I would follow the C.D.C. recommendations.

Just to emphasize: I do not have empirical data that simple masks work for the coronavirus. But we do know they work for other respiratory viruses. So what we are trying to do is extrapolate. There is no empirical evidence that Im aware of that going to the grocery store with a mask will protect you more than anything else from the coronavirus. But with other viruses, including ones that behave similarly, it helps.

What sort of face coverings should we be using if we dont have access yet to professionally made masks?

The quick answer is that I dont know and we dont know. I would vastly prefer that if we are going to ask the public to use masks, the C.D.C. or someone should give us very clear guidelines on what works and what doesnt work. There is a study from Cambridge University in which they tested a number of household materials, ranging from cloth to linen, against the size of a typical respiratory droplet. The study suggested that T-shirts and pillowcases worked fine. Again, we are operating with little data. Surgical masks are the most effective in this study. Then a vacuum-cleaner bag and then a dish towel. Then a cotton-blend T-shirt. So that is probably a reasonable item to use in a double layer.

The problem is that if we have a free-for-all, and say you can make your own, then there is no control over it. Some people will make things that are really good, and some people will make things that are terrible. And we will think they are all identical and move right along. It would be very helpful if we could standardize this and have a decontamination protocol for public use.

Has the science changed on masks at all recently? Or has this always been what it has been?

There is more science now. There are more papers for SARS, which show that, in the hospital, a simple surgical mask, in conjunction with hand hygiene and social distancing, vastly decreased the infection rate. The problem with science is that it cant catch up with what people are doing on the side. If everyone says they are going to use their own material, then science cant catch up with it, because we dont know what you are using. So there is more science, but the science has to go hand in hand with the social shifts. And it would seem to me that, rather than the President saying to cover your mouth with a scarf, having a scientific, centralized way to distribute it, produce it free of charge, and make everyone wear it, and have a decontamination protocol would be crucial.

Make everyone wear it, or suggest that they do?

I would suggest it, and if it really makes a dent, then put out a public-service announcement saying everyone should wear it. You cant force people to adopt behaviors in this country, although you can make it very uncomfortable for people who show up without masking because of social pressures. But I dont think it should be compulsory. I do think that, given the seriousness of what is going on, given the paralysis in the economy, and the desire for people to get back to work, I think there should be some sense of social responsibility, and if it really decreases the chance of infecting others and yourself, and if people agree universally to wear it, I think we could potentially convince the vast majority of the people to wear a mask.

Does this contradict what you said earlier about not wanting to shame people who dont wear it? Could we get to a point where we should be shaming people who dont?

I think shame is not the best mechanism for getting people to wear it. I think the better mechanism is for everyone to understand that there is a sense of social responsibility that they have, and adopting that social responsibility is part of what we do as a country to prevent economic collapse. If we dont get back to work by June or Julyhopefully, there will be medicines by then. But there will not be vaccines, and if we want to get back to work by June or July, I strongly suggest that we find mechanisms by which we can get back to work with masks.

Lots of evidence has shown that masked countries are doing better than unmasked ones in terms of spread. Do you attribute that to the masks?

Its very hard, because there is no trial and we have to believe the evidence at face value. There was a meme going around Twitter showing that countries with masks were doing better, but then someone superimposed that same meme and instead of masks they wrote bubble tea and no bubble. It is suggestive, but it is an unknowable, because no one did the experiment, and the scientist in me has to say that its an unknowable because there is no direct evidence that the countries wearing masks were more successful in decreasing the rise in infections.

And, in South Korea, say, it could be about something else, like testing.

It could be about testing. Yes.

Is mask wearing something that would generally be healthy and cut down on other diseases and flu deaths? Is this a societal change we should be making or thinking about apart from the coronavirus?

We know, again, from a vast amount of scientific evidence that viruses that are secreted through respiratory secretions and cough droplets, including influenza and SARS, are decreased in their exposure when people wear masks. So, under conditions when the infections are spreading fast, the evidence suggests that mask wearing really decreases the chance of infecting others and getting infected yourself. And the return on the so-called R0 of the virus may be quite large. So I think in conditions such as now, when there is exponential spread of the virus, I think that would be the right thing to do.

Here is the original post:
What We Know About Masks and the New Coronavirus - The New Yorker

TISSUE REGENERATION TECHNOLOGIES Announces That Its First Coronavirus Clinical Trial Has Been Initiated Utilizing Unfocused Shockwave Therapy…

(MENAFN - Newswire) ATLANTA,April 11, 2020(Newswire.com) - Tissue Regeneration Technologies (TRT) announced today an important addition to our patent family to potentially aid in the fight against the Coronavirus. This patent applies the known mechanisms of action of unfocused shockwaves against this deadly virus. It is documented that the application of shock waves can produce the following effects in vivo:

Stem cell activation

Modulation of inflammation

Blood flow improvement

Antimicrobial and antiviral

Dislodging, liquefaction and dilution of viscous fluids such as phlegm

All of these effects may aid in the fight against the Coronavirus. The last bullet point may allow for life-threatening mucous to be expelled more efficiently. As shockwaves pass through tissue types with differing acoustic properties (lung tissues and thick mucus produced by COVID type viruses), energy is released at the interfaces, which is theorized to contribute to the dislodging of mucus that has been observed immediately after treatment. Additionally, the known anti-inflammatory properties of shockwaves may modulate the inflammatory overreaction initiated by COVID-19. Finally, the reparative properties of Shockwaves, including the activation of resident stem cells, may aid in the recovery and regeneration of damaged lung tissue.

John Warlick, CEO states, 'the most exciting development is that we have initiated our first clinical trial enrolling those patients where both ventilators and ECMO (Extracorporeal Membrane Oxygenation) have failed to stabilize the patient. Based on the fast-acting mechanism of action discussed above, we hope to release the initial results very soon. We have been very cautious to develop our unfocused Shockwave (SoftWave) therapy for the treatment of the lungs as there are many misconceptions about the risks associated with shockwaves and lung tissue developed from the thirty plus years of utilizing high energy, focused shockwaves to destroy kidney stones. TRT's unique, patented low energy unfocused shockwaves do not adversely affect lung tissue as previously feared. This has been demonstrated with extensive invitro and invivo trials.'

CEO John Warlick further states, 'TRT has assembled a team of doctors, engineers, and physicists to support this Herculean effort to eradicate the virus in the lungs. More importantly, TRT will release an open-source 'white paper' site for others to contribute to this project. This project is too critical to handle on our own. We need to enlist additional experts in this endeavor. We know shockwaves influence most of the known biologic pathways to disrupt viral replication and aid in the support of the patient's recovery. We are very confident in the outcome of our fight to destroy the effects of the virus.'

' Ironically, a virus is a very fragile agent. Others seek very elaborate, expensive technologies to fight viruses. Sometimes you just need a sonic hammer. At the most basic level, shockwaves are just a biologic hammer triggering a basic biological response.'

Pleasereview the attached PDF below for full release.

MENAFN1304202000704191ID1100019367

See more here:
TISSUE REGENERATION TECHNOLOGIES Announces That Its First Coronavirus Clinical Trial Has Been Initiated Utilizing Unfocused Shockwave Therapy...

Michael Schumacher health: The truth about the F1 champ’s recovery after a devastating head injury in 2013 – EconoTimes

Michael Schumachers exact health condition is still a mystery up to now. His familys efforts to guard him against the media and the public eyes proved to be successful as people dont really know how he is doing today. There is no single photograph of the F1 racing champ since suffering from a severe head injury while skiing in the Alps with his family in December 2013.

Today, most of what people know about Schumi came from his close friends or sometimes from the medical professionals who cared for or treated him. But is he really recovering well just like what his friends and family are saying?

Early days after the accident

Immediately after Michael Schumacher bumped his head on a rock while skiing with his son, he was found unconscious due to traumatic head injury. He was airlifted to Hospital of Moutiers and then brought to Grenoble University Hospital Center, a bigger medical facility where he could get the treatment he needed at that time.

Doctors declared him in critical condition due to the severity of his brain trauma. Before 2014, he was put into an induced coma so he could be saved. He underwent brain surgery to stop the bleeding in his head.

There were reports that he passed away already, but the Grenoble University Hospital denied the rumors and announced on February 14 that Michael Schumacher is still alive. Since then, theres a media blackout about Schumacher but he was said to have woken up already after six months in a comatose state.

"He is sleeping, he looks normal and he showed a few responses with his mouth," Express quoted Felipe Massa, a Ferrari teammate who visited Schumi in the hospital. "I was very happy to be able to spend some time with him. I really hope that he will again be able to enjoy life."

The truth on Schumis condition today

Over six years after his accident, it was said that Michael Schumacher is recovering well as his family has been taking good care of him. It was claimed that he underwent stem-cell therapy in September last year but it appeared that this did not help him much.

As per The Daily Mail, the surgeon who performed the procedure on the F1 legend stated that he doesnt perform miracles which could mean that the treatment, even if it is considered as one of the breakthroughs in this age, did not heal Michael Schumacher. In another report, a surgeon stated that Schumi is very different now as the truth is - because of his prolonged medication and illness, his health is deteriorating.

"We must imagine a person very different from the one we remember on the track, with a very altered and deteriorated organic, muscular and skeletal structure," Nicola Acciari, a surgeon, told Ovacion Uno. All as a result of the brain trauma he suffered."

View post:
Michael Schumacher health: The truth about the F1 champ's recovery after a devastating head injury in 2013 - EconoTimes

Michael Schumacher health: Timeline of F1 champion’s recovery bid – Express.co.uk

Michael Schumacher retired in 2012 as a seven-time F1 world champion and is widely regarded as one of the sport's greatest drivers of all time. However, the following year, the German racer suffered traumatic head injuries while on a skiing trip with his family.

Schumacher - who was wearing a helmet - fell and hit his head on a rock in the French Alps.

The 51-year-old has not been seen in public since the accident and updates on his health have been scarce.

December 29, 2013: Schumacher is airlifted to Hospital of Moutiers following the accident and later transported to Grenoble University Hospital Centre, where doctors said he was "suffering a serious brain trauma with coma on his arrival, which required an immediate neurosurgical operation".

December 30, 2013: Schumacher is said to be in "critical condition" as surgeons operate to stop brain haemorrhaging and treat intracranial pressures.

The former F1 star is placed in a medically induced coma.

ALSO SEE: What Michael Schumacher once told Bernie Ecclestone revealed by legend

January 1, 2014: Schumacher's condition is said to have improved slightly after the second operation but doctors added he was "not out of danger".

January 7, 2014: Schumacher's wife, Corinna, speaks publically for the first time since her husband's accident.

In a statement, she asked media at the Grenoble hospital to leave to "ease the burden on the doctors and the hospital so that they can do their work in peace".

She added: "Please also leave our family alone."

January 31, 2014: Doctors begin to gradually wake Schumacher up from the medically induced coma.

February 2014: Grenoble University Hospital confirm that Schumacher is still alive following reports the former F1 driver had died.

Schumachers agent, Sabine Kehm, says he is still in the wake-up phase from an induced coma.

Former Ferrari team-mate Felipe Massa also visits Schumacher in hospital and provides a brief update.

"He is sleeping, he looks normal and he showed a few responses with his mouth," said Massa.

"I was very happy to be able to spend some time with him. I really hope that he will again be able to enjoy life."

London neurosurgeon Colin Shieff says it is unlikely Schumacher will make a full recovery.

"The fact that he hasn't woken up implies that the injury has been extremely severe and that a full recovery is improbable," said Shieff.

March 2014: Kehm says there are "small and encouraging signs" the German's condition is improving.

Schumacher is moved to the University Hospital of Lausanne in Switzerland, close to his family home in Geneva.

June 2014: Schumacher is no longer in a medically induced coma.

July 2014: Corinna says her husband has begun to recognise her voice.

September 2014: Schumacher's recovery continues at his private home in Geneva, Switzerland.

A statement read: "Michael's rehabilitation will take place at his home.

"Considering the severe head injuries he suffered, progress has been made in the past weeks and months. There is still, however, a long and difficult road ahead."

2015: FIA president Jean Todt says the former Ferrari driver is "still fighting".

2016: Kehm says Schumacher's family are struggling to come to terms with the accident but hope he will "one day be back with us".

2017: Schumacher's lawyer was forced to tell a court the F1 legend "cannot walk" after an article by German magazine Bunte claimed he was walking. Bunte magazine had to pay 50,000 in damages.

2018: Corinna issues a brief update.

"It is good to receive so many kind wishes and other well-intentioned words - which is a great support for our family," she says.

"We all know Michael is a fighter and will not give up."

2019: Jean Todt, Schumacher's former Ferrari boss, says the star is "making good progress".

"Im always careful with such statements, but its true," said Todt. "I saw the race together with Michael Schumacher at his home in Switzerland."

Schumacher reportedly goes to the Georges-Pompidou hospital in Paris to undergo pioneering stem cell treatment.

The hospital neither confirms nor denies this, however, an unnamed nurse tells French outlet Le Parisien that Schumacher is conscious after a stem-cell procedure.

2020: Nicola Acciari, a leading neurosurgeon, says "we must imagine a person very different from the one we remember on the track, with a very altered and deteriorated organic, muscular and skeletal structure".

"All as a result of the brain trauma he suffered," she added.

See the original post here:
Michael Schumacher health: Timeline of F1 champion's recovery bid - Express.co.uk